Pharmacokinetics and Acceptability of Once- Versus Twice-Daily Lamivudine and Abacavir in HIV Type-1-Infected Ugandan Children in the ARROW Trial

Antiviral Therapy- United Kingdom

doi 10.3851/imp1695

Full Text

Abstract

Available in

Categories

Infectious Diseases

Date

January 1, 2010

Authors

Lindsay Kendall

Sabrina Bakeera-Kitaka

Wendy B Snowden

Florence Odongo

Margaret Thomason

Philippa Musoke

Kimberly Adkison

Adeodata Kekitiinwa

Publisher

International Medical Press

Related search

Pharmacokinetic Study of Once-Daily Versus Twice-Daily Abacavir and Lamivudine in HIV Type-1-Infected Children Aged 3-<36 Months

Antiviral Therapy

Infectious Diseases

English

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

Journal of Acquired Immune Deficiency Syndromes

Infectious Diseases

English

Covariate Effects and Population Pharmacokinetics of Lamivudine in HIV-infected Children

British Journal of Clinical Pharmacology

English

Pharmacokinetics and Pharmacodynamics of Glimepiride in Type 2 Diabetic Patients: Compared Effects of Once- Versus Twice-Daily Dosing

Endocrine Journal

English

Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

New England Journal of Medicine

English

Pharmacokinetics of Generic and Trade Formulations of Lamivudine, Stavudine and Nevirapine in HIV-infected Malawian Children

Antiviral Therapy

Infectious Diseases

English

96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study

Antiviral Therapy

Infectious Diseases

English

Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma

Respiratory Research

Respiratory Medicine

English

Once Versus Twice Daily Fractionation for Limited Stage SCLC

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English